Jharkhand Magazine

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Ischemic Stroke Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.

Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years. 
• Acute Ischemic Stroke companies working in the treatment market are Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme Bio Technology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, Genentech, and others, are developing therapies for the Acute Ischemic Stroke treatment 
• Emerging Acute Ischemic Stroke therapies such as – ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS-007), 3K3A-APC, Nerinetide, Nelonemdaz, Tenecteplase, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.   
• In February 2022 A Phase II, two-part, double-blind, randomised, placebo-controlled trial was started by Lumosa Therapeutics Co., Ltd. to assess the safety and effectiveness of the LT3001 medicinal product in patients having endovascular thrombectomy (EVT) for acute ischemic stroke (AIS). When necessary, subjects who take part in this experiment should receive standard of care (SoC) AIS therapy. 66 people are now participating in the study, which is expected to be finished by April 2024
• In May 2022, “Randomization to Endovascular Treatment Alone orPreceded by Systemic Thrombolysis with Tenecteplase in Acute Ischemic Stroke Due to Large Intracranial Vessel Occlusion Trial- DIRECT Thrombectomy vs. Intravenous TNK plus Thrombectomy” is the name of the study that Boehringer Ingelheim started
• In July 2022, The European Medicines Agency (EMA) granted “PRIority Medicines” designation to ACTICOR BIOTECH for its therapeutic candidate, glenzocimab, for the treatment of stroke victims.With early conversations with regulatory agencies and stronger engagement as a result of this status, Acticor Biotech was able to confirm the clinical development strategy for the treatment of stroke with glenzocimab
• In July 2022, In a groundbreaking preclinical study, the University of Cincinnati and Case Western Reserve University (CWRU) showed that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was started up to 7 days after onset. This information was released by NervGen Pharma
• In June 2021, A Phase III Multi-center, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Evaluate the Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients with Acute Ischemic Stroke within 4.5 Hours after Stroke Onset was started by Boehringer Ingelheim

Acute Ischemic Stroke Overview

There is some overlap in risk factors and clinical presentation between ischemic and hemorrhagic acute stroke, and each requires fundamentally different care. It is a medical emergency brought on by the brain’s decreasing blood supply, which damages brain cells.

Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight

Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

• ST-01: Saillant Therapeutics
• AVLX 144: Avilex Pharma
• NTS-104: NeuroTrauma Science
• PP-007: Prolong Pharmaceutical
• UMSC01: Ever Supreme Bio Technology
• NCS-01: NC Medical Research, Inc
• LT3001: Lumosa Therapeutics Co., Ltd.
• NONO-SC: NoNO Inc.
• RNS60: Revalesio Corporation
• BIIB131 (TMS-007): Biogen
• 3K3A-APC: ZZ Biotech
• Nerinetide: NoNO Inc
• Nelonemdaz: GNT Pharma
• Tenecteplase: Genentech

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Acute Ischemic Stroke Pipeline Therapeutics Assessment

• Acute Ischemic Stroke Assessment by Product Type
• Acute Ischemic Stroke By Stage and Product Type
• Acute Ischemic Stroke Assessment by Route of Administration
• Acute Ischemic Stroke By Stage and Route of Administration
• Acute Ischemic Stroke Assessment by Molecule Type
• Acute Ischemic Stroke by Stage and Molecule Type

DelveInsight’s Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies

Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Acute Ischemic Stroke are – Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

Acute Ischemic Stroke Pipeline Analysis:

The Acute Ischemic Stroke pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Ischemic Stroke with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
• Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies

Acute Ischemic Stroke Pipeline Market Drivers

• Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Acute Ischemic Stroke Market.

Acute Ischemic Stroke Pipeline Market Barriers

• However, Challenges associated with the clinical research, challenges associated with the diagnosis of Acute Ischemic Stroke and other factors are creating obstacles in the Acute Ischemic Stroke Market growth.

Scope of Acute Ischemic Stroke Pipeline Drug Insight    

• Coverage: Global
• Key Acute Ischemic Stroke Companies: Saillant Therapeutics, Avilex Pharma, NeuroTrauma Science, Prolong Pharmaceutical, Ever Supreme Bio Technology, NC Medical Research, Inc., Lumosa Therapeutics Co., Ltd., Revalesio Corporation, Biogen, ZZ Biotech, NoNO Inc., GNT Pharma, Genentech, and others
• Key Acute Ischemic Stroke Therapies: ST-01, AVLX 144, NTS-104, PP-007, UMSC01, NCS-01, LT3001, RNS60, BIIB131 (TMS-007), 3K3A-APC, Nerinetide, Nelonemdaz, Tenecteplase, and others
• Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers 

Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services